In our study among five patients with EGFR TKI-sensitive mutations in mediastinal lymph node metastases, there were four patients who showed tumor regression in response to EGFR TKI and underwent surgery. This evidence concerns the gene EGFR and metastatic malignant neoplasm in the lymph nodes.